JFG
INDV icon

Jefferies Financial Group’s Indivior Pharmaceuticals INDV Stock Holding History

Jefferies Financial Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$622K – 1801
2024
Q4 		$622K Sell
50,000
-2,500
-5% -$25.7K ﹤0.01% 1048
2024
Q3 		$512K Buy
52,500
+2,500
+5% +$29.3K ﹤0.01% 970
2024
Q2 		$806K Buy
+50,000
New +$902K 0.01% 822

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's INDV Position: Q2 2026 in Review

Jefferies Financial Group sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 507,909 shares — an estimated $15.5M sold.

Jefferies Financial Group first reported a position in INDV in Q2 2023 and held it in 12 quarters. The position peaked at $32.5M in Q2 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Jefferies Financial Group reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 507,909 Indivior Pharmaceuticals shares in Q2 2026, an estimated $15.5M.
  • Jefferies Financial Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 12 quarters.
  • Jefferies Financial Group's Indivior Pharmaceuticals position peaked at $32.5M in Q2 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.